Understand the source comparison
Epithelioid versus Sarcomatoid Histology: Research Model Considerations
MPM presents in three histological subtypes — epithelioid (~60%, better prognosis), sarcomatoid (~20%, worst prognosis, minimal immune infiltration), and biphasic (~20%, mixed). These subtypes have profoundly different TME biology and peptide research relevanc
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- MPM presents in three histological subtypes — epithelioid (~60%, better prognosis), sarcomatoid (~20%, worst prognosis, minimal immune infiltration), and biphasic (~20%, mixed). These subtypes have profoundly different TME biology and peptide research relevance. Epithelioid MPM (NCI-H2452, JMN cell lines) maintains epithelial characteristics with moderate immune infiltration; Tα1 immune biology research is most relevant in this subtype where TIL priming is feasible. Sarcomatoid MPM (VAMT-1 cell line) shows EMT-complete biology (E-cadherin absent, vimentin high, ZEB1/Snail nuclear) — GHK-Cu and BPC-157 anti-EMT biology may be more mechanistically relevant in these lines.
- The AB12 syngeneic model (BALB/c intrapleural) represents epithelioid MPM biology. For sarcomatoid research, VAMT-1 xenograft in SCID/NSG mice is standard. Intrapleural injection technique (27G needle, intercostal 4th space, 0.2 mL volume) and ultrasound monitoring of pleural effusion volume (as primary tumour readout) are used at specialist UK research centres.